

INVESTOR RELATIONS

MetrioPharm Investor Relations News QII 2019

13th Annual General Meeting of MetrioPharm AG

On June 18, 2019, the 13th Annual General Meeting of MetrioPharm AG was held in Kaufmännischer Verband (Zurich). The Management and the Board of Directors of MetrioPharm AG presented the annual report for 2018 at the beginning of the meeting. Focal points were the refinancing of MetrioPharm AG through two capital increases, as well as the status quo of the ongoing clinical psoriasis Phase II study. MetrioPharm recently announced that the last patient was now examined (Last Patient Last Visit). The primary goal of the study is to evaluate clinical efficacy and safety of MP1032 in various dosages. The final results (Top Line Data) are expected within the next few months.

The annual report and the annual financial statements were approved, followed by the unanimous discharge of the Board of Directors. Dr. Werner Wolf and Markus Wenner were re-elected to the Board of Directors for a further three-year term of office. Ferax Treuhand AG was newly re-elected into the role as auditor.

Of the total share capital of CHF 24'704'000, divided into 123'520'000 registered shares with a par value of CHF 0.20 each, 87'338'018 shares were represented. This corresponds to 70.98 % of the issued shares. The voting results for the 13th Annual General Meeting can be found in detail on our website under MetrioPharm AG: Voting Results.

MetrioPharm at the J.P. Morgan Conference “Life Sciences – from San Francisco to Zurich”, Zurich, Switzerland

On April 11, 2019, J.P. Morgan and Euronext organized the Life Sciences conference titled “From San Francisco to Zurich”. It was addressing exclusively invited healthcare investors. Wolfgang Brysch, CEO of MetrioPharm AG and Eva Brysch, Head of Investor Relations, were presenting the company to an interested audience. “It was a very interactive event in an exclusive circle of experts and investors. The exchange with investors, organizers and other Life Science companies was very fruitful for MetrioPharm. We are grateful for the invite and would love to return”, Eva Brysch comments.

MetrioPharm in Philadelphia, USA

Once again, this year, MetrioPharm AG was able to take advantage of one of the biggest business partnering events taking place, worldwide. MetrioPharm AG visited BIO International in Philadelphia, in order to expand already existing contacts, as well as establishing new relationships. More than 30 one-on-one meetings, primarily with pharma

partners from Asia, served as a forum to exchange results, linked to the MP1032 compound. Furthermore, the ongoing Phase II clinical trial for psoriasis was discussed. Here the final results are expected within the next few months. MetrioPharm was represented at the conference by Dr. Wolfgang Brysch (CEO), Barry Frankel (Senior Vice President Strategy and Business Development) and Felix Edler (Business Development).

MetrioPharm in Madrid, Spain

From June 12th till June 15th 2019, the EULAR European Congress of Rheumatology took place in Madrid, Spain. MetrioPharm AG was represented by Dr. Astrid Kaiser, Head of Drug Development, and Dr. Petra Schulz, Senior Project Manager Drug Development. Schulz comments: "The EULAR Conference was a great opportunity for us to gain insight into the world of rheumatology. The presentations were of high quality, put together by health professionals and scientists, which were all focused on improving the well-being of people effected by RMD (rheumatic musculoskeletal diseases). We were able to receive valid updates on what is new in the field of rheumatoid arthritis and we identified new possible positionings for MP1032 in other rheumatic musculoskeletal diseases. There is an unmet medical need for new innovative drugs where MP1032 with its unique MoA could show promising effects. It was a great pleasure to participate."

MetrioPharm AG Company Calendar in QIII 2019

25-26th September 2019: 19th Annual Biotech in Europe Forum, Basel, Switzerland

MetrioPharm AG's CEO Wolfgang Brysch will be representing MetrioPharm AG at this conference. He will be partaking as a panelist, covering the subject of autoimmune and inflammatory diseases.

Should further dates be added for the third quarter, you can find out more on our website at www.metriopharm.com.

New Member for MetrioPharm AG's Corporate Communications/Investor Relations Team

Lia Petridou is working since June 1st on the Corporate Communications/Investor Relations team for MetrioPharm AG. She will be particularly focused on interests and matters of the ever-growing MetrioPharm AG investor community, worldwide.

Phase II Clinical Trial in Psoriasis

In mid-June, the last psoriasis patients were treated in MetrioPharm's Phase II clinical trial. Our teams have already started validating the data. Simultaneously, we are preparing for unblinding and statistical analysis. In this context, MetrioPharm CEO Dr. Wolfgang Brysch addresses the question: How safe is MP1032? And why is that so important to us?

Please find the entire article on our blog.

Your contact:



Eva Brysch
Head of Investor Relations & Corporate Communications
Tel.: +49-(0)30-3384-395-40
E-Mail: invest@metriopharm.com